# Venetoclax and Decitabine in R/R T-ALL

> **NCT06712121** · PHASE2 · RECRUITING · sponsor: **Seoul National University Hospital** · enrollment: 28 (estimated)

## Conditions studied

- T Lymphoblastic Leukemia/Lymphoma

## Interventions

- **DRUG:** decitabine plus venetoclax

## Key facts

- **NCT ID:** NCT06712121
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-30
- **Primary completion:** 2027-08-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06712121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06712121, "Venetoclax and Decitabine in R/R T-ALL". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06712121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*